Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

被引：5
|
作者：
Richardson, Paul G. [1 ]
Mitsiades, Constantine S. [1 ]
Colson, Kathleen [1 ]
Reilly, Eileen [2 ]
McBride, Laura [2 ]
Chiao, Judy
Sun, Linda
Ricker, Justin L. [3 ]
Rizvi, Syed [3 ]
Oerth, Carol [3 ]
Atkins, Barbara [3 ]
Fearen, Ivy
Anderson, Kenneth C. [1 ]
Siegel, David S. [2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.1179.1179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1179
引用
收藏
页码：357A / 357A
页数：1
相关论文
共 50 条
  • [41] Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy.
    Duvic, M
    Talpur, R
    Zhang, C
    Goy, A
    Richon, V
    Frankel, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 577S - 577S
  • [42] Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia
    Gojo, Ivana
    Tan, Ming
    Fang, Hong-Bin
    Sadowska, Mariola
    Lapidus, Rena
    Baer, Maria R.
    Carrier, France
    Beumer, Jan H.
    Anyang, Bean N.
    Srivastava, Rakesh K.
    Espinoza-Delgado, Igor
    Ross, Douglas D.
    CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1838 - 1851
  • [43] Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03)
    Wen, P. Y.
    Puduvalli, V.
    Kuhn, J.
    Reid, J.
    Cloughesy, T.
    Yung, W. A.
    Chang, S. M.
    Robbins, H. I.
    McGovern, R.
    Ames, M.
    Prados, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Vorinostat (suberoylanilide hydroxamic acid-SAHA) as salvage therapy in metastatic breast cancer (BC): a California cancer consortium phase II study.
    Luu, T.
    Morgan, R. J.
    Leong, L.
    Frankel, P.
    Lim, D.
    McNamara, M.
    Portnow, J.
    Chew, H.
    Lentz, H-J
    Belani, C.
    Aparicio, A.
    Gandara, D. R.
    Somlo, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S74 - S74
  • [45] A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non Hodgkin lymphoma. A California cancer consortium study
    Kirschbaum, Mark H.
    Zain, Jasmine M.
    Popplewell, Leslie
    Pullarkat, Vinod
    Nademanee, Auayporn P.
    Delioukina, Maria L.
    Pulone, Bernadette
    Matsuoka, Deron
    Frankel, Paul
    James, Zwiebel A.
    Forman, Stephen J.
    Newman, Edward
    Gandara, David
    BLOOD, 2007, 110 (11) : 757A - 757A
  • [46] A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)
    Goncalves, Priscila Hermont
    Kummar, Shivaani
    Siu, Lillian L.
    Hansen, Aaron Richard
    Savvides, Panayiotis
    Sukari, Ammar
    Chao, Joseph
    Heilbrun, Lance K.
    Pilat, Mary Jo
    Smith, Daryn W.
    Casetta, Lindsay
    Boerner, Scott Anthony
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously
    Kelly, WK
    Richon, VM
    O'Connor, O
    Curley, T
    MacGregor-Curtelli, B
    Tong, W
    Klang, M
    Schwartz, L
    Richardson, S
    Rosa, E
    Drobnjak, M
    Cordon-Cordo, C
    Chiao, JH
    Rifkind, R
    Marks, PA
    Scher, H
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3578 - 3588
  • [48] N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)
    Galanis, E.
    Jaeckle, K. A.
    Maurer, M. J.
    Reid, J. M.
    Ames, M. M.
    Giannini, C.
    Hardwick, J. S.
    Moore, D. F., Jr.
    Zwiebel, J. A.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
    Duvic, M
    Talpur, R
    Chiao, N
    Chiao, J
    BLOOD, 2003, 102 (11) : 179A - 180A
  • [50] A PHASE 2 STUDY OF VORINOSTAT (SUBEROYLANILIDE HYDROXAMIC ACID, SAHA) IN RELAPSED OR REFRACTORY INDOLENT NOW HODGKIN'S LYMPHOMA. A CALIFORNIA CANCER CONSORTIUM STUDY
    Kirschbaum, M.
    Popplewell, L.
    Nademanee, A.
    Pullarkat, V.
    Delioukina, M.
    Zain, J.
    Matsuoka, D.
    Pulone, B.
    Frankel, P.
    Forman, S.
    Espinoza-Delgado, I.
    Newman, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 166 - 166
12345